Articles tagged "Malignancy"

2016 American Transplant Congress
Incidence of Post-Transplant Malignancy (PTM) After Pediatric Kidney Transplantation (PKTx).
O. Serrano,¹ A. Bangdiwala,² D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ B. Chavers.³
¹Surgery, Univ. of Minnesota, Minneapolis, MN; ²Biostatistics, Univ. of Minnesota, Minneapolis, MN; ³Pediatrics, Univ. of Minnesota, Minneapolis, MN.
PURPOSE: Post-transplant immunosuppression is associated with an increase in cancer rates. To date, the long-term incidence of PTM among PKTx recipients has not been well-characterized.METHODOLOGY:…
2016 American Transplant Congress
The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.
M. Ningappa, B. Higgs, S. Ranganathan, C. Ashokkumar, R. Sindhi.
Surgery, Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh, Pittsburgh, PA.
Background: Hepatoblastoma, the most common pediatric liver malignancy, is cured by chemotherapy and surgical resection. Locally invasive/multifocal tumors require liver transplantation (LTx). A unique tumor…
2016 American Transplant Congress
Stratifying Skin Versus Non-Skin Cancer Risk Post-Kidney Transplantation According to Patient Characteristics.
F. Jackson-Spence,¹ H. Gillott,¹ S. Tahir,¹ F. Evison,² J. Nath,³ A. Sharif.³
¹University of Birmingham Medical School, Birmingham, United Kingdom; ²Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; ³Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Introduction Cancer is a significant cause of morbidity and mortality after kidney transplantation but risk differs e.g. non-melanoma skin cancers have a better prognosis compared…
2016 American Transplant Congress
Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study.
C. Pettenati,¹ A.-S. Jannot,² V. Verkarre,³ S. Hurel,¹ H. Kreis,⁴ M. Housset,⁵ C. Legendre,⁴ A. Méjean,¹ M.-O. Timsit.¹
¹Department of Urology and Transplant surgery, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ²Department of Statistics, Computing and Public Health, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ³Department of Pathology, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁴Department of Nephrology and Transplantation, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁵Department of Onco-Radiotherapy, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France.
Objective To analyze prostate cancer characteristics in a contemporary monocentric renal transplant recipients (RTR) population and to compare oncological outcome after radical prostatectomy (RP) with…
2016 American Transplant Congress
Beyond the Bones – The Association Between Vitamin D, Graft Outcomes and Vascular Disease.
A. Cherukuri,¹ S. Balasubramanian,² R. Molyneux,² R. Baker.
¹UPMC, Pittsburgh; ²University of Leeds, Leeds, United Kingdom.
Background: Vitamin D deficiency in KTRs is an emerging theme. The purported associations between Vitamin D deficiency and various metabolic, cardiovascular and non-metabolic adverse events…
2016 American Transplant Congress
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.
R. Patel,¹ I. Feurer,¹ S. Karp,¹ L. Gillis,¹ H. Katzenstein,¹ H. Lovvorn III,¹ J. Pietsch,¹ D. Chung, G. Tiao,² D. Hanto.¹
¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Background: Hepatoblastoma (HB), hepatocellular carcinoma (HCC), along with hemangioendothelioma, hemangiosarcoma, and angiosarcoma (HHA) are rare tumors in children that are treated with orthotopic liver transplantation…
2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
D. Dahle,¹ T. Grotmol,² T. Leivestad,³ A. Hartmann,¹ G. Mjøen,¹ H. Pihlstrøm,¹ H. Næss,¹ H. Holdaas.¹
¹Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway; ²The Cancer Registry of Norway, Oslo, Norway; ³Norwegian Renal Registry, Oslo University Hospital, Oslo, Norway.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…
2016 American Transplant Congress
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.
E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.
Stanford School of Medicine, Stanford, CA.
EBV is linked to a variety of lymphoid and epithelial malignancies. In transplant recipients EBV is associated with the development of B cell lymphomas in…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…